Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease

Leuzy, A., Bollack, A., Pellegrino, D., Teunissen, C. E., La Joie, R., Rabinovici, G. D., Franzmeier, N., Johnson, K., Barkhof, F., Shaw, L. M., Arkhipenko, A., Schindler, S. E., Honig, L. S., Moscoso Rial, A., Schöll, M., Zetterberg, H., Blennow, K., Hansson, O., & Farrar, G. (2025). Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer’s disease. Alzheimer’s & Dementia, 21(3). Portico. https://doi.org/10.1002/alz.14528
Authors:
Antoine Leuzy
Ariane Bollack
Daniela Pellegrino
Charlotte E Teunissen
Renaud La Joie
Gil D Rabinovici
Nicolai Franzmeier
Keith Johnson
Frederik Barkhof
Leslie M Shaw
Alexander Arkhipenko
Suzanne E Schindler
Lawrence S Honig
Alexis Moscoso Rial
Michael Schöll
Henrik Zetterberg
Kaj Blennow
Oskar Hansson
Gill Farrar
Affiliated Authors:
Lawrence S Honig
Columbia Affiliation:
Subjects:
Alzheimer Disease (MeSH)
Positron-Emission Tomography (MeSH)
Biomarkers (MeSH)
Amyloid beta-Peptides (MeSH)
Author Keywords:
alzheimer
aβ‐pet
csf
biomarkers
diagnosis
elink
Publication Type:
Article
Unique ID:
10.1002/alz.14528
PMID:
40042435
DOI:
10.1002/alz.14528
Journal:
Alzheimer's and Dementia
Publication Date:
Data Source:
PubMed
Source Link:
View PubMed Record

Record Created: